For appropriately selected patients with muscle-invasive bladder cancer, bladder preservation can be a curative treatment option, according to a new clinical guideline from the American Society for Radiation Oncology (ASTRO). The recommendations support trimodal therapy (maximal transurethral resection of bladder tumor followed by chemoradiation for bladder preservation) as an alternative to radical cystectomy and provide guidance on the use of radiation therapy after surgery and for patients with metastatic or symptomatic disease. The guideline, ASTRO’s first focused specifically on radiation therapy across bladder cancer care, was published by Ballas et al in Practical Radiation Oncology.
A lower-cost chemoimmunotherapy approach including triple oral metronomic chemotherapy (TMC) combined with ultra-low-dose immunotherapy termed TMC-I could extend survival for patients with advanced head and neck squamous cell carcinoma in resource-limited countries, according to investigators from India who reported results with the novel regimen at the 2026 ASCO Annual Meeting.1
In the large, platform-based, independent validation study CATALINA, published by Dixon-Douglas et al in The Lancet Oncology, two artificial intelligence (AI)-derived computational tumor-infiltrating lymphocyte (cTIL) models, which were deployed without retraining or modification, provided statistically significant prognostic information and improved risk discrimination beyond clinicopathologic variables alone in patients with early-stage triple-negative breast cancer.
Cancer mortality associated with alcohol use has risen in the United States, disproportionately affecting males and adults aged at least 55 years, according to a population-based observational trend analysis published by Jani et al in The Lancet Regional Health – Americas.
Artificial intelligence could reshape health care by reducing administrative work, helping physicians identify and manage disease, and extending care beyond traditional clinical settings—potentially allowing caregivers to focus more on patient care and human interaction, according to Cleveland Clinic executive leaders.
Three studies presented at the 2026 ASCO Breakthrough conference in Singapore focused on problems that can derail cancer care even when treatment is otherwise on track: nausea after starting morphine, continued smoking after a cancer diagnosis, and unrecognized frailty in older adults. Although the ...
A multi-cancer early detection test named Galleri from the health-care company GRAIL received a favorable vote from the Molecular and Clinical Genetics Devices Panel of the U.S. Food and Drug Administration (FDA) Medical Devices Advisory Committee. The Committee voted for approval of the premarket...
I was just 24 and in seemingly perfect health when I began experiencing unexplained abdominal pain so excruciating, even daily doses of pain medication failed to provide relief. I was a senior in college and had enrolled in a summer internship program at the University of California, Davis, when my ...
For many men with low-risk prostate cancer, active surveillance means living with cancer while delaying—or potentially avoiding—surgery or radiation therapy. It also leaves many patients asking what they can do beyond “wait and watch.” Findings presented at the 2026 American Urological Association...
A multimodal artificial intelligence (AI) model incorporating multiscale histopathology features was able to predict recurrence risk in patients with early-stage hormone receptor–positive and HER2-negative breast cancer more accurately than the 21-gene recurrence score, Oncotype DX, according to...
On September 4, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to camizestrant (Etcamah), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, HER2-negative...
New updates to the College of American Pathologists’ (CAP) Cancer Protocols will affect breast cancer biomarker reporting and molecular testing for gastrointestinal stromal tumors (GISTs), reflecting advances in precision oncology and laboratory accreditation. The updates are part of revisions to...